Rau, Daniela
Eichau, Sara
Borriello, Giovanna
Cerqueira, João
Wagner, Carola
Funding for this research was provided by:
Novartis Pharma GmbH and Novartis Pharma AG funded this study
Article History
Received: 28 February 2022
Accepted: 28 March 2023
First Online: 10 April 2023
Declarations
:
: From a legal or regulatory point of view, there is no obligation for all of the participating countries (Germany, Italy, Portugal and Spain) to submit this type of survey to an ethics committee. The questionnaire of the survey was subject to review and approval by the German Novartis "Ethics, Risks & Compliance" department. The Novartis "Ethics, Risks & Compliance" departments of all participating countries (Germany, Italy, Portugal and Spain) approved the conduct of the survey in the respective countries. All the participated physicians provided written informed consent to participate in the survey, to the collection and processing of their personal data and to the following agreement:<i>“The Contractual Partner acknowledges and recognizes that Novartis is member of the German Industry Association FSA ("Voluntary Self-regulation for the Pharmaceutical Industry") and this data collection complies with the industry standards and rules of the Industry Association, in particular the FSA Code of Conduct for the cooperation of the pharmaceutical industry with healthcare professionals.”</i>There was no inclusion of patient data at any point in time throughout the survey. Therefore, no written patient informed consent is required.
: Not applicable.
: DR received research support, travel grants, consultancy fees and speaker fees from Bayer Healthcare, Biogen, Celgene, Lilly, Merck, Novartis, Roche, Sanofi Genzyme, Teva and Zambon.SE received speaker honoraria and consultant fees from Biogen Idec, Novartis, Merck, Bayer, Sanofi Genzyme, Roche, Almirall and Teva.GB received consultant fee and grant for trip and Congress registration from Almirall, Biogen, Merck, Novartis, Roche, Teva, Sanofi Genzyme.JC has received compensation for participation in clinical trials, presence in advisory boards and as a speaker from Roche, Novartis, Sanofi, Almirall, Zambon, Biogen, Janssen, Merck and Bristol-Myers-Squibb and research funding from Biogen, Merck, Roche and Fundação BIAL.CW is an employee of Novartis.